The present study was designed to investigate the possibility of using Lactobacillus as a skin probiotic. For this purpose, 63 isolates of Lactobacillus sp. were collected from dairy products and human mouth samples. The isolates were screened for bacteriocin production by primary and secondary screening against three common skin pathogens. The results showed that the isolate Lactobacillus HT1give the highest productivity of bacteriocin (320AU/ml), the efficient isolate was identified through molecular detection using 16S ribosomal RNA gene. In addition, result showed that L. acidophilus HT1 was un encapsulated; has no capability to produce biofilm and was susceptible to amoxicillin–clavulanic acid, vancomycin and chloramphenicol. Moreover, the infectious dose of L. acidophilus HT1 was studied and results revealed that mice were remained in a healthy condition including all vital processes such as breathing, consuming food and water as well as external and anatomical appearance. Next, an emul gel formula contained L. acidophilus HT1 biomass was prepared which already examined in vitro and in vivo. Our results confirmed the efficacy of the formula via inhibiting the growth of pathogenic isolates and through several points included: viability of L. acidophilus HT1 cells, its ability to produce bacteriocin, and its releasing from the formula to the external environment without trapping or interaction among bacteriocin and any component of formula. In vivo results approved the affectivity of L. acidophilus HT1 biomass to treat the wounds infected with different bacterial pathogens during seven days after the onset of treatment compared with the control groups.
This study was aimed to purified and characterized the bacteriocin produced from Lactobacillus acidophilus HT1, in order to use it in a skin pharmaceutical formula. The optimal conditions for bacteriocin production was investigated and results showed that modified nutrient broth was the best medium with glucose (30 gm/L) and yeast extract (7 gm/L) with peptone (7 gm/L) were the optimum carbon and nitrogen sources. In addition, 2% inoculum size, 37C◦ and pH 6.4 were the optimal conditions to obtain maximum bacteriocin of 640 AU/ml after 24 hrs. The bacteriocin was purified using 70% ammonium salt saturation and gel filtration with sephadex G50 that resulted 20 % yield and 2560 AU/ml of activity, then the partial purified bacteriocin was characterized and found the bacteriocin was protein in nature and kept its activity after 10 min at 20, 30 and 40◦C, however 50% of the activity was lost at 50C◦. Moreover, it showed stability at pH 6 and 7 for 30 min whereas; no activity was observed at pH 4 and 9. In addition, results showed that bacteriocin has a bactericidal effect rather than bacteriostatic. A cream formula contained the bacteriocin was prepared which already examined in vitro and in vivo. The effectiveness of the formula was confirmed using Klebsiella sp., Staphylococcus aureus and Pseudomonas aeruginosa as indicator strains. Results established that treatment at the onset time was more effective and the time of healing was decreased.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.